Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers

Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE)

July 23, 2020 7:01 AM EDT

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) after speaking with a KOL about the company's hemophilia franchise. The doctor said that conventional thinking is that gene therapy will last 5-10 years, but... More